Glucocorticoid hormones, acting via nuclear receptors, regulate many metabolic processes, including hepatic gluconeogenesis. It recently has been recognized that intracellular glucocorticoid concentrations are determined not only by plasma hormone levels, but also by intracellular 11␤-hydroxysteroid dehydrogenases (11␤-HSDs), which interconvert active corticosterone (cortisol in humans) and inert 11-dehydrocorticosterone (cortisone in humans). 11␤-HSD type 2, a dehydrogenase, thus excludes glucocorticoids from otherwise nonselective mineralocorticoid receptors in the kidney. Recent data suggest the type 1 isozyme (11␤-HSD-1) may function as an 11␤-reductase, regenerating active glucocorticoids from circulating inert 11-keto forms in specific tissues, notably the liver. To examine the importance of this enzyme isoform in vivo, mice were produced with targeted disruption of the 11␤-HSD-1 gene. These mice were unable to convert inert 11-dehydrocorticosterone to corticosterone in vivo. Despite compensatory adrenal hyperplasia and increased adrenal secretion of corticosterone, on starvation homozygous mutants had attenuated activation of the key hepatic gluconeogenic enzymes glucose-6-phosphatase and phosphoenolpyruvate carboxykinase, presumably, because of relative intrahepatic glucocorticoid deficiency. The 11␤-HSD-1 ؊͞؊ mice were found to resist hyperglycamia provoked by obesity or stress. Attenuation of hepatic 11␤-HSD-1 may provide a novel approach to the regulation of gluconeogenesis.
Glucocorticoids (cortisol in humans, corticosterone in mice and rats) are an important class of adrenocorticosteroids that regulate many metabolic and homeostatic processes and form a key component of the response to stress (1). Glucocorticoids act via intracellular glucocorticoid receptors and, in some tissues, mineralocorticoid receptors; both are nuclear transcription factors (2). Recently, it has become apparent that glucocorticoid action on target tissues depends not only on circulating steroid concentrations and the cellular expression of receptors, but also on intracellular enzymes that critically determine if glucocorticoids gain access to receptors in active forms.
11␤-hydroxysteroid dehydrogenase (11␤-HSD) catalyzes the interconversion of cortisol and corticosterone with their inert 11-keto forms [cortisone and 11-dehydrocorticosterone (11-DHC), respectively]. There are two isozymes. 11␤-HSD type 2 (11␤-HSD-2) is a high affinity (nanomolar K M ), NADdependent exclusive 11␤-dehydrogenase (3, 4), which excludes glucocorticoids from otherwise nonselective mineralocorticoid receptors in aldosterone target tissues, such as the distal nephron (5, 6) , and from the feto-placental unit (4) . Mutations of the gene encoding 11␤-HSD-2 are responsible for the human syndrome of ''apparent mineralocorticoid excess,'' characterized by illicit activation of renal mineralocorticoid receptors by cortisol, producing sodium retention, severe hypertension, and hypokalemia (7) (8) (9) .
In contrast, the function(s) of 11␤-HSD type 1 (11␤-HSD-1), initially purified and cloned from rat liver (10, 11) , remain obscure. 11␤-HSD-1 shares less than 30% homology with 11␤-HSD-2, has a lower affinity for glucocorticoids (micromolar K M ), and uses NADP(H) as cosubstrate. High expression of 11␤-HSD-1 is found in the liver, lung, adipose tissue, kidney, and brain, largely localized to cells expressing glucocorticoid receptors, but not mineralocorticoid receptors, suggesting that 11␤-HSD-1, by analogy to 11␤-HSD-2, modulates glucocorticoid access to glucocorticoid receptors (12) . 11␤-HSD-1 in tissue homogenates and when purified is bidirectional, exhibiting both 11␤-dehydrogenase and 11␤-reductase reactions, with greater stability of the dehydrogenase activity (10) . However, though transfection of Chinese hamster ovary cells with 11␤-HSD-1 cDNA encodes bidirectional activity (11) , transfection of the same cDNA into other cell lines encodes a predominant 11␤-reductase (13, 14) , which regenerates active glucocorticoids from inert 11-keto forms. The reductase reaction predominates in intact cells, whereas broken cells, homogenates, and microsomes all show bidirectional activity. Importantly, primary cultures of rat hepatocytes, lung cells, hippocampal cells, and vascular smooth muscle cells (15) (16) (17) (18) ) also show predominant 11␤-reductase activity, which parallels 11␤-HSD-1 mRNA expression (15) . Such glucocorticoid regeneration, if manifest in vivo, might increase effective intracellular glucocorticoid levels, amplifying glucocorticoid activity. To explore this notion further we generated mice bearing targeted disruption of the 11␤-HSD-1 gene.
MATERIALS AND METHODS
Cloning and Mapping Mouse 11␤-HSD-1 Gene. A 129͞Ola GEM-12 genomic library was screened with a rat 11␤-HSD-1 cDNA probe. A 14-kb 11␤-HSD-1 genomic fragment encompassing exons 2-5 was cloned and mapped by partial restriction digestion, subcloning of gene fragments, and crosshybridization of purified fragments. Sequencing of exons 2, 3, 4, and 5 showed complete concordance with the published mouse cDNA sequence (19) .
Construction of Replacement Vector and Gene Targeting. The replacement vector was based on plasmid pBS-␤KnpA16 containing the neomycin resistance gene flanked by the human ␤-actin promoter and the simian virus 40 polyadenylation signal sequence. A 6.5-kb KpnI-SpeI fragment from intron D of the 11␤-HSD-1 gene was modified by blunt-ending the SpeI site and subcloned between the KpnI and EcoRV sites of pBS-␤KnpA16 to produce pBS-LA1, the 3Ј homology arm subclone. The 5Ј homology arm was synthesized by generating a 1.2-kb PCR fragment by using oligonucleotides with nested SacI and SpeI restriction sites (oligo 1: TTTGAGCTCTAC-AAATGAAGAGTTCAGAC; oligo 2: CCCACTAGTGAG-AGTTTAAGTCTATTGTT) and subcloned between SacI and SpeI sites of pBS-LA1 to produce pBS-ko16x16. This replacement vector was linearized with KpnI and SacI and electroporated into embryonic stem (ES) cells (line CGR 8) (20) . G-418 resistant clones were selected as described (20) , and DNA was extracted and analyzed by PCR. Two positive controls were run for each DNA sample to amplify products of Ϸ1.3 kb: oligo 4 (CACTGCATTCTAGTTGTGGTTTGT-CC) and oligo 1 amplified the sequence from the integrated replacement vector, and oligo 3 (TTTGGATCCCACCCAA-AGCCAATCATTGC) and oligo 2 amplified from the wildtype allele. PCR with oligo 3 and oligo 4 amplified any specific integration event. Specific recombination was confirmed by Southern blot hybridization of BamHI-digested DNA with a 180-bp PCR-derived external probe located between Ϫ87 and ϩ87 relative to the transcription start. Cells from the targeted ES cell clone were injected into C57BL͞6 blastocysts and transferred into C57BL͞CBA foster mothers. Chimeras were bred to MF1 females, and the progeny was genotyped by Southern analysis of BamHI-digested DNA.
Gene Expression and Enzyme Function Analysis. Tissue 11␤-HSD-1 mRNA expression was determined by Northern analysis, as described (19) . 11␤-HSD activity was quantitated in homogenates, as described (21) . Briefly, tissues were homogenized in Krebs-Ringer bicarbonate buffer and incubated with 200 M NADP (NAD for 11␤-HSD-2), 12 nM [ 3 H]-corticosterone and 0.2% BSA for 60 min, before extraction and analysis of steroids by HPLC. 11␤-ketosteroid reductase activity was assayed by using [ 3 H]-11-DHC (8-80nM) at multiple time points by using 0.25 mg protein͞ml in 10% glycerol, 1 mM EDTA, 50 mM sodium acetate pH 6.0 buffer, and 200 M NADPH (22) . [ 3 H]-11-DHC was prepared as described (22) . The apparent K M was calculated by using Lineweaver-Burke plots.
Analysis of Corticosterone and 11-DHC Metabolites. Hepatic exposure to corticosterone and 11-DHC was analyzed by quantitation of urinary tetrahydro metabolites (tetrahydrocorticosterone, allo-tetrahydrocorticosterone, and tetrahydro-11-DHC) by using GC-MS. Briefly, urinary steroids together with conjugates were purified from C18 Sep-pak columns, and conjugates were hydrolyzed with ␤-glucuronidase and rechromatographed. Analysis of trimethylsilyl-methoxime derivatives was carried out by using a Hewlett Packard 5890 gas chromatograph, fitted with a HP-1 crosslinked methylsiloxane column (25 m, id.0.25 mm, ft.0.17 m) coupled to a Trio-1000 mass spectrometer. Quantitation used deuterated standards (23, 24) . Plasma corticosterone levels in morning (basal) and evening (peak) samples were measured by radioimmunoassay (25) , modified for microtiter plate scintillation proximity assay (Amersham).
Adrenal Sensitivity to ACTH in Vitro. Mice were housed singly for 2 days before experimentation. Adrenals were removed from 11␤-HSD-1 ϩ͞ϩ and Ϫ͞Ϫ mice, cleaned, halved, and incubated in vitro in 1 ml of MEM (containing 25 mM Hepes and 0.1% wt͞vol BSA). After preincubation for 120 min, the medium was changed and adrenals incubated for 60 min to determine basal corticosterone production. ACTH (0.1-10 nmol͞liter) was applied for an additional 60 min, and medium was removed and frozen until analysis of corticosterone by radioimmunoassay (as above).
In Vivo Studies Measurement of 11-Hydroxysteroid Reductase Activity in Vivo. Twenty-four male, 3-month-old 11␤-HSD-1 ϩ͞ϩ and Ϫ͞Ϫ mice were bilaterally adrenalectomized under halothane anesthesia and a pellet, 50% 11-DHC (15 mg 11-DHC ϩ 15 mg cholesterol) or placebo (30 mg cholesterol), inserted s.c. After 3 days, mice were decapitated, trunk blood was taken, the thymuses were weighed, and the abdomens were examined to ensure no adrenal tissue remained. Plasma corticosterone was measured by radioimmunoassay. Any circulating corticosterone would be because of the conversion of 11-DHC to corticosterone by tissues in vivo.
Unstressed blood glucose measurements. Mice were housed singly for 24 hr and fasted overnight. All blood glucose measurements were made between 08.30-09.30 hr. Mice were removed from their cages and loosely restrained in a box. A rapid tail-nick procedure was carried out within 30-60 sec of disturbing the animal, before stress-induced glucose mobilization could occur. Whole blood glucose was measured by the glucose oxidase method by using a One Touch II Glucometer (Lifescan, UK).
Stressed fasting glucose levels. Mice were fasted overnight and then exposed to a new cage (a potent psychological stressor in rodents) for 60 min. After cervical dislocation, trunk blood samples were obtained and plasma glucose was measured, as described (26) .
High-fat diet. Mice were housed 3-5 per cage and fed either a normal diet (chow) ad libitum or a high-fat diet (60% loose chow, 10% granulated sugar, and 30% margarine fat).
Hepatic enzyme activities and glycogen content. Mouse liver microsomes and cytosol were prepared, microsomes were disrupted (27) , and glucose-6-phosphatase (G6Pase), phosphoenolpyruvate carboxykinase (PEPCK), and glucokinase activities assayed, as described (28) (29) (30) . Kinetic constants were calculated by nonlinear regression analysis. Glycogen (31) and protein concentrations were measured, as described (32) .
RESULTS
A null mutation of the 11␤-HSD-1 locus was generated by replacing the genomic fragment encompassing exons 3 and 4 with a neomycin-resistance cassette, through specific recombination in mouse ES cells (Fig. 1 a and b) . Specific recombination was detected in one of 368 G418-resistant colonies screened by PCR. Targeting was confirmed by Southern analysis with 5Ј external and 3Ј internal probes. Southern analysis with the internal probe confirmed a single site of integration (not shown). Cells from a single targeted ES clone (1C5), confirmed to have a normal karyotype, were injected into C57BL͞6 blastocysts. Of six male chimeras born, germline transmission was achieved in one, which was mated to MF 1 females. Approximately half of the progeny were heterozygous for the disrupted allele. Homozygous (11␤-HSD-1 Ϫ͞Ϫ) mice were bred by intercross and backcross of MF 1 ͞129 heterozygotes. In 150 animals genotyped, no deviation from Mendelian distribution of alleles was observed, with the distribution of classes in the intercross 44 (ϩ͞ϩ):78 (ϩ͞Ϫ):34 (Ϫ͞Ϫ). No 11␤-HSD-1 mRNA was detected by Northern analysis of liver RNA from 11␤-HSD-1 Ϫ͞Ϫ homozygous mutants, whereas heterozygotes (11␤-HSD-1 ϩ͞Ϫ) showed Ϸ50% reduction of 11␤-HSD-1 mRNA expression (Fig. 1c) . Hepatic 11␤-HSD activity was Ͻ5% of wild-type levels in homozygous mutants (Fig. 1d) . There was no detectable 11␤-ketosteroid reductase activity in liver homogenates from 11␤-HSD Ϫ͞Ϫ mutant mice; the K m for 11-DHC (11␤-reductase) was 120 Ϯ 10 nM in wild-type liver. No 11␤-HSD-1 mRNA or enzyme activity was detected in Ϫ͞Ϫ brains. Activity of the 11␤-HSD-2 To investigate the effect of 11␤-HSD-1 gene knockout on the net production of corticosterone from exogenous 11-DHC, adrenalectomized wild-type and Ϫ͞Ϫ mice were implanted with 11-DHC pellets (15 mg) and plasma corticosterone was measured 3 days later. Whereas wild-type adrenalectomized mice could readily convert 11-DHC to active corticosterone, achieving plasma levels Ϸ250 nmol͞liter, in Ϫ͞Ϫ animals plasma corticosterone remained undetectable (Ͻ10 nmol͞ liter; Fig. 2a) . Moreover, 11-DHC pellets led to thymic involution (a glucocorticoid-dependent process) in wild type, but not Ϫ͞Ϫ mice (Fig. 2b ). These data demonstrate that 11␤-HSD-1 is the sole 11␤-reductase activity converting inert 11-ketosteroids into active glucocorticoids under physiological conditions and can generate sufficient corticosterone to confer physiological effects.
The adrenal glands of male 11␤-HSD-1 Ϫ͞Ϫ mice were significantly enlarged (3.15 Ϯ 0.2 mg; n ϭ 18) in comparison to weight-and age-matched wild-type controls (1.85 Ϯ 0.17 mg; n ϭ 16; P Ͻ 0.05 Student's t test); morphometric analysis suggested adrenocortical hyperplasia. Moreover, the adrenals of male 11␤-HSD-1 Ϫ͞Ϫ mice incubated in vitro showed increased basal and ACTH-stimulated corticosterone secretion (Fig. 3) .
In vivo and basal (morning, diurnal nadir) plasma corticosterone levels were higher in 11␤-HSD-1 Ϫ͞Ϫ mice (62 Ϯ 14 nmol͞liter, n ϭ 10) than in wild types (33 Ϯ 4 nmol͞liter, P Ͻ 0.05, n ϭ 10). Peak (evening) levels of plasma corticosterone did not differ significantly (149 Ϯ 20 nmol͞liter in wild type, 106 Ϯ 20 nmol͞liter in Ϫ͞Ϫ mice). The ratio of tetrahydro 11-DHC to tetrahydro-corticosterone derivatives, largely generated in the liver, in pooled 24-hr urine samples was 0.62. This ratio predicts the concentration of 11-DHC reaching the liver in wild-type mice to be in the limits between 20 and 90 nM.
To determine nonstressed glucose levels, mice were habituated to rapid sampling by tail nick without handling. This experiment revealed no fasting hypoglycemia in Ϫ͞Ϫ mice. However, feeding the mice a high-fat diet, previously reported to produce obesity and defective glycemic control (33) , showed that obese 11␤-HSD-1 Ϫ͞Ϫ mice had significantly lower fasting plasma glucose levels than weight-matched wild-type controls (Fig. 4) . Similarly, after 24-hr starvation combined with novel environment stress, plasma glucose levels were significantly lower in Ϫ͞Ϫ mice (5.6 Ϯ 0.4 mmol͞liter; n ϭ 14) than in wild types (6.7 Ϯ 0.3 mmol͞liter; n ϭ 13; P Ͻ 0.05). 11␤-HSD-1 Ϫ͞Ϫ mice had normal basal levels of hepatic G6Pase and PEPCK mRNA and activity. However, on starvation, 11␤-HSD-1 Ϫ͞Ϫ mice failed to show the normal induction of G6Pase and PEPCK (Table 1) . The effects on G6Pase were particularly striking and predominantly affected the enzyme itself rather than the G6P transporter, because similar effects occurred in intact and disrupted microsomes. Hepatic glucokinase and its fall on starvation were unaltered in the Ϫ͞Ϫ animals. However, liver glycogen levels in Ϫ͞Ϫ mice were significantly increased in the fed state compared with wild types (Table 1) .
DISCUSSION
Our data suggest that 11␤-HSD-1 is a unique enzyme in the mouse, converting inert 11-keto corticosteroids into active glucocorticoids, and indicate this conversion has important consequences for intracellular glucocorticoid action, notably in the liver. The mice appear normal at birth, findings in concert with the low expression of this isozyme in most fetal tissues (34) . Although 11␤-HSD-1 is expressed in rodent placenta and 11␤-HSD inhibitors reduce birth weight in rats (26, 35) , no alterations in birth weight in 11␤-HSD-1 Ϫ͞Ϫ mice were found, suggesting these studies reflect effects on 11␤-HSD-2, itself highly expressed in fetus and placenta (36) . Both male and female 11␤-HSD-1 Ϫ͞Ϫ mice are fertile and produce normal litters. Although 11␤-HSD-1 is expressed in the rat testis (37) and ovary (38) and has been suggested to regulate fertility in males (39), this does not appear to be the case, at least in mice.
In the absence of 11␤-HSD-1 reductase, inert 11-keto corticosteroids cannot be reduced to active 11-hydroxy forms. Our data suggest that significant amounts of 11-DHC reach the liver, as judged by the Ϸ2:3 ratio of urinary tetrahydro-11-DHC metabolites to tetrahydrocorticosterone metabolites (largely generated in liver), allowing an estimate of plasma 11-DHC levels of around 50 nM, a value according with plasma Proc. Natl. Acad. Sci. USA 94 (1997) 14927 levels of cortisone, the human equivalent (40) . The 120 nM K M for reduction of 11-DHC in wild-type liver is also clearly appropriate to metabolize nanomolar levels of circulating 11-DHC; enzyme activity was not detected in the liver homogenates of 11␤-HSD-1 Ϫ͞Ϫ animals. If the lack of 11-DHC reactivation to corticosterone is of importance in overall glucocorticoid production and tissue activation, it might be anticipated that there would be increased drive from the hypothalamic-pituitary-adrenal axis to restore homeostasis. Intriguingly, adrenal hyperplasia has been described in a unique female patient with presumed 11␤-reductase deficiency (41) . This contention is further supported in 11␤-HSD-1 null mice, in which adrenal weight is increased, caused, in large part, by increased adrenal cortical size. This finding appears to be of functional significance because the null mice showed increased secretion of corticosterone to ACTH stimulation in vitro. Indeed, plasma corticosterone levels actually were elevated at the diurnal nadir (morning). This result suggests not only increased adrenal corticosterone secretion in vivo, but also relative insensitivity of the hypothalamic-pituitary-adrenal axis to central glucocorticoid inhibition; 11␤-HSD-1 is expressed in the hippocampus, hypothalamus, and pituitary in wild-type, but not Ϫ͞Ϫ mice, and in normal rats (42) (43) (44) . Loss of function of central 11␤-HSD-1 reductase thus may attenuate effective glucocorticoid feedback, as appears to occur at least for some hypothalamic corticotroph secretagogues (44) .
Glucocorticoids stimulate transcription of hepatic gluconeogenic enzymes and thus play a major role in the enhancement of liver glucose output during starvation or stress (45) . PEPCK and G6Pase catalyze the rate-limiting steps of gluconeogenesis. Transcription of genes encoding both enzymes is regulated by classical glucocorticoid-inducible promoters (46, 47) and is markedly attenuated in glucocorticoid receptor-deficient mice (48) . Our results indicate that glucocorticoid reactivation by 11␤-HSD-1 also plays a critical role in the up-regulation of these genes during starvation. Thus in 11␤-HSD-1 Ϫ͞Ϫ mice, the expected induction of hepatic G6Pase mRNA and enzyme activity on starvation was lost and PEPCK induction was attenuated, the lesser effect presumably reflecting complex regulation of the PEPCK promoter by both glucocorticoid and cAMP response elements (49) and mirroring data from glucocorticoid receptor knockout mice (48) . Similarly, elevated liver glycogen in fed null mice presumably reflects attenuated glycogenolysis, a pathway normally stimulated by glucocorticoids in the fed state (Table 1) (45) . These results are unlikely merely to reflect generalized or nonspecific effects of the mutation on liver function, because glucokinase activity and its fall with starvation (which show complex regulation) are unaffected in Ϫ͞Ϫ mice. Presumably in consequence of these changes, the null mice resist the hyperglycemia seen in the wild-type litter mates with stress or obesity. Thus, the 11␤-HSD-1 Ϫ͞Ϫ liver appears to reproduce a phenotype of partial glucocorticoid deficiency, despite somewhat increased basal plasma corticosterone levels.
These experiments suggest that intracellular regeneration of corticosterone in the liver from inert circulating 11-DHC contributes more to effective intracellular corticosterone concentrations than plasma corticosterone itself. Indeed, 11-DHC circulates mainly unbound, whereas corticosterone is predominantly bound to corticosteroid binding globulin (CBG). CBG has a substantial excess capacity for corticosterone (50) such that for most of the day ''free'' corticosterone concentrations are low (Ͻ5 nmol͞liter), only reaching levels comparable to 11-DHC during the diurnal peak or stress response. We believe that by eliminating 11␤-HSD-1 gene function we have created an animal model of relative intracellular glucocorticoid deficiency. This model will be particularly useful for investigating the action of glucocorticoids on tissues (liver, brain, lung, and vasculature) where reactivation of 11-keto steroids by 11␤-HSD-1 may occur. The study also raises the notion of 11-DHC and cortisone as prohormones, with plasma levels not subjected to wide diurnal fluctuations (40) or sequestration by CBG (51) , and which may possess higher tissue specificity because they can act only on tissues expressing 11␤-HSD-1. Finally, the resistance of 11␤-HSD-1 Ϫ͞Ϫ mice to stress and obesity-related hyperglycemia suggests that inhibition of this enzyme may attenuate gluconeogenesis (52) . The relevance of this finding to disease processes, such as noninsulin-dependent diabetes mellitus, remains to be explored. 
